Neural Regeneration Research ›› 2017, Vol. 12 ›› Issue (4): 558-561.doi: 10.4103/1673-5374.205085

Previous Articles     Next Articles

Endothelial progenitor cells as a therapeutic option in intracerebral hemorrhag

Juan Pías-Peleteiro, Francisco Campos, José Castillo, Tomás Sobrino   

  1. Clinical Neurosciences Research Laboratory, Department of Neurology, Stroke Unit, University Clinical Hospital, Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
  • Received:2017-03-07 Online:2017-04-15 Published:2017-04-15
  • Contact: Tomás Sobrino, Ph.D. or José Castillo, Ph.D., tomas.sobrino.moreiras@sergas.es or jose.castillo.sanchez@sergas.es.
  • Supported by:

    This study has been partially supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2014-56336), the Instituto de Salud Carlos III (PI13/00292 & PI14/01879), the Spanish Research Network on Cerebrovascular Diseases (RETICS INVICTUS; RD12/0014), the Xunta de Galicia (Department of Education, GRC2014/027), and the European Union program FEDER. Furthermore, F. Campos (CP14/00154) and TS (CP12/03121) are recipients of a research contract from Miguel Servet Program of Instituto de Salud Carlos III. The funders had no role in the review design, data collection and analysis, decision to publish, or preparation of the manuscript.

PDF

564

Abstract:

Intracerebral hemorrhage (ICH) is the most severe cerebrovascular disease, which represents a leading cause of death and disability in developed countries. However, therapeutic options are limited, so is mandatory to investigate repairing processes after stroke in order to develop new therapeutic strategies able to promote brain repair processes. Therapeutic angiogenesis and vasculogenesis hold promise to improve outcome of ICH patients. In this regard, circulating endothelial progenitor cells (EPCs) have recently been suggested to be a marker of vascular risk and endothelial function. Moreover, EPC levels have been associated with good neurological and functional outcome as well as reduced residual hematoma volume in ICH patients. Finally, experimental and clinical studies indicate that EPC might mediate endothelial cell regeneration and neovascularization. Therefore, EPC-based therapy could be an excellent therapeutic option in ICH. In this mini-review, we discuss the present status of knowledge about the possible therapeutic role of EPCs in ICH, molecular mechanisms, and the future perspectives and strategies for their use in clinical practice.

Key words: cellular therapy, endothelial progenitor cells, growth factors, intracerebral hemorrhage, neurorepair, outcome